Invivyd reports preliminary Q4 2025 revenue $17.2M, VYD2311 Phase 3 trial initiated, top-line data mid-2026

Invivyd, Inc.

2025-FY EPS reported -$0.30 vs consensus -$0.09 ▼ miss (-235.9%)

Preliminary Q4 2025 PEMGARDA net product revenue of $17.2M, up 25% YoY from $13.8M and 31% QoQ from $13.1M.
Ending 2025 cash and cash equivalents of $226.7M after raising over $200M in 2H 2025.
Initiated DECLARATION Phase 3 pivotal trial of VYD2311 for COVID prevention; top-line data expected mid-2026.
Fast Track designation for VYD2311 granted by FDA in December 2025.
Selected potential best-in-class RSV antibody candidate VBY329; IND readiness targeted for 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.